{"id":67099,"date":"2026-06-02T14:34:24","date_gmt":"2026-06-02T06:34:24","guid":{"rendered":"https:\/\/flcube.com\/?p=67099"},"modified":"2026-06-02T14:34:25","modified_gmt":"2026-06-02T06:34:25","slug":"servier-group-acquires-edgewise-therapeutics-muscular-dystrophy-business-for-up-to-2-65-billion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67099","title":{"rendered":"Servier Group Acquires Edgewise Therapeutics&#8217; Muscular Dystrophy Business for Up to $2.65 Billion"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Servier Group<\/strong>, the French pharmaceutical company, announced a definitive agreement to acquire the <strong>muscular dystrophy business<\/strong> of <strong>Edgewise Therapeutics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/EWTX:NASDAQ\">NASDAQ: EWTX<\/a>) for <strong>total consideration of up to USD 2.65 billion<\/strong>, including an <strong>upfront payment of USD 1.55 billion<\/strong> and <strong>up to USD 1.1 billion in regulatory and commercial milestones<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-details-amp-financial-structure\" class=\"wp-block-heading\">Transaction Details &amp; Financial Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Servier Group (France)<\/td><\/tr><tr><td><strong>Target Business<\/strong><\/td><td>Edgewise Therapeutics&#8217; muscular dystrophy portfolio<\/td><\/tr><tr><td><strong>Total Consideration<\/strong><\/td><td>Up to <strong>$2.65 billion<\/strong><\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>$1.55 billion<\/strong><\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to <strong>$1.1 billion<\/strong> (regulatory and commercial)<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Q3 2026<\/td><\/tr><tr><td><strong>Transaction Scope<\/strong><\/td><td>R&amp;D capabilities, technologies, and sevasemten asset<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-sevasemten-first-in-class-muscle-protector\" class=\"wp-block-heading\">Asset Profile: Sevasemten \u2013 First-in-Class Muscle Protector<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Sevasemten \u2013 oral fast skeletal myosin inhibitor<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> First-in-class approach designed to protect fragile muscles from contraction-induced injury<\/li>\n\n\n\n<li><strong>Indications:<\/strong><\/li>\n\n\n\n<li><strong>Becker muscular dystrophy (BMD)<\/strong> \u2013 pivotal cohort study ongoing<\/li>\n\n\n\n<li><strong>Duchenne muscular dystrophy (DMD)<\/strong> \u2013 Phase II clinical study active<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral formulation for convenient chronic dosing<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses root cause of muscle damage rather than symptomatic management<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-rare-disease-landscape\" class=\"wp-block-heading\">Market Context &amp; Rare Disease Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Muscular Dystrophy Prevalence<\/strong><\/td><td>DMD affects ~15,000-20,000 patients in US\/EU; BMD affects ~10,000-15,000 patients<\/td><\/tr><tr><td><strong>Current Treatment Limitations<\/strong><\/td><td>Corticosteroids provide modest benefit with significant side effects; no disease-modifying therapies approved for BMD<\/td><\/tr><tr><td><strong>Sevasemten Differentiation<\/strong><\/td><td>First therapy specifically designed to prevent contraction-induced muscle damage<\/td><\/tr><tr><td><strong>Commercial Potential<\/strong><\/td><td>Ultra-orphan designation likely supports premium pricing ($500K-$1M annually per patient)<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Aligns with Servier&#8217;s rare disease focus and complements existing neuromuscular portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-integration-plan\" class=\"wp-block-heading\">Strategic Implications &amp; Integration Plan<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Expansion:<\/strong> Significantly strengthens Servier&#8217;s position in ultra-rare neuromuscular disorders<\/li>\n\n\n\n<li><strong>Development Acceleration:<\/strong> Servier&#8217;s global infrastructure expected to accelerate pivotal studies and regulatory filings<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> Existing Servier rare disease commercial teams can rapidly deploy upon approval<\/li>\n\n\n\n<li><strong>R&amp;D Synergies:<\/strong> Integration of Edgewise&#8217;s muscle biology platform with Servier&#8217;s drug development expertise<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Transaction represents one of the largest rare disease acquisitions of 2026<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition provides Servier with a late-stage, first-in-class asset addressing significant unmet medical needs in devastating rare muscle diseases, while offering Edgewise shareholders substantial value realization and de-risking the development pathway through Servier&#8217;s established rare disease capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition transaction, clinical development plans, and commercial expectations. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4766,4767,1496],"class_list":["post-67099","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-edgewise-therapeutics","tag-nasdaq-ewtx","tag-servier-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Servier Group Acquires Edgewise Therapeutics&#039; Muscular Dystrophy Business for Up to $2.65 Billion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67099\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Servier Group Acquires Edgewise Therapeutics&#039; Muscular Dystrophy Business for Up to $2.65 Billion\" \/>\n<meta property=\"og:description\" content=\"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67099\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T06:34:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T06:34:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Servier Group Acquires Edgewise Therapeutics&#8217; Muscular Dystrophy Business for Up to $2.65 Billion\",\"datePublished\":\"2026-06-02T06:34:24+00:00\",\"dateModified\":\"2026-06-02T06:34:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Edgewise Therapeutics\",\"NASDAQ: EWTX\",\"Servier Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67099#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67099\",\"name\":\"Servier Group Acquires Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T06:34:24+00:00\",\"dateModified\":\"2026-06-02T06:34:25+00:00\",\"description\":\"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67099\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67099#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Servier Group Acquires Edgewise Therapeutics&#8217; Muscular Dystrophy Business for Up to $2.65 Billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Servier Group Acquires Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion - Insight, China&#039;s Pharmaceutical Industry","description":"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67099","og_locale":"en_US","og_type":"article","og_title":"Servier Group Acquires Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion","og_description":"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.","og_url":"https:\/\/flcube.com\/?p=67099","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T06:34:24+00:00","article_modified_time":"2026-06-02T06:34:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67099#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67099"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Servier Group Acquires Edgewise Therapeutics&#8217; Muscular Dystrophy Business for Up to $2.65 Billion","datePublished":"2026-06-02T06:34:24+00:00","dateModified":"2026-06-02T06:34:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67099"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Edgewise Therapeutics","NASDAQ: EWTX","Servier Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67099#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67099","url":"https:\/\/flcube.com\/?p=67099","name":"Servier Group Acquires Edgewise Therapeutics' Muscular Dystrophy Business for Up to $2.65 Billion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T06:34:24+00:00","dateModified":"2026-06-02T06:34:25+00:00","description":"Servier Group, the French pharmaceutical company, announced a definitive agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for total consideration of up to USD 2.65 billion, including an upfront payment of USD 1.55 billion and up to USD 1.1 billion in regulatory and commercial milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67099#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67099"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67099#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Servier Group Acquires Edgewise Therapeutics&#8217; Muscular Dystrophy Business for Up to $2.65 Billion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67099"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67099\/revisions"}],"predecessor-version":[{"id":67100,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67099\/revisions\/67100"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}